Category: Investment, Biotech, Pharma

Biotech stocks News; Biotechnology Industry (NASDAQ: BPAX) on the Upswing - BioSante and Cardium Therapeutics Look to Rally

The Paragon Report Provides Equity Research on BioSante Pharmaceuticals & Cardium Therapeutics

Visit this company: www.biosantepharma.com

NEW YORK, NY - January 17, 2012 (Investorideas.com newswire) - Biotechnology stocks have been on fire of late. The iShares Biotechnology index is up more than 12 percent over the last month as investors brace for big drug launches, FDA hearings, and greater M&A activity in the coming months. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cardium Therapeutics Inc. (AMEX:CXM). Access to the full company reports can be found at:

www.paragonreport.com/BPAX www.paragonreport.com/CXM

J.P. Morgan's Healthcare Conference in San Francisco this month offered an appealing venue for biotechs to target potential deals in 2012. According to Henry Gosebruch, managing director of health-care mergers and acquisitions at JPMorgan Chase & Co, the analyst firm expects "the large biotechs to be active acquirers in 2012." Gosebruch added that "investors have rewarded strategic acquisitions that enhance long-term growth and companies that continue their history of developing innovative therapies, as opposed to turning into dividend paying, share-repurchase type low-growth stocks."

According to a recent report from Bloomberg, biotech companies have historically been less active than their pharmaceutical industry counterparts regarding M&A activity. For example, over the past 4 years, Bristol-Myers has completed an impressive 17 acquisitions, while biotech industry heavyweight, Celgene, has completed a mere 3 acquisitions.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cardium Therapeutics, Inc. focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs, and definable pathways to partnering, commercialization, and other monetizations. Earlier this month the company announced that it has entered into its first international agreement for the commercialization of Excellagen in the South Korean market. Cardium had recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell its Excellagen professional-use, sterile, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Contact:

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com

or

For Media:
Harris D. McKinney, Inc.
Alan Zachary
312-506-5220
azachary@harrisdmckinney.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX and other stocks http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: Investorideas.com is paid by BPAX to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs (six thousand five hundred per three months of publishing)

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  

Source: Investorideas.com, BioSante, Investorideas.com

800 665 0411 cvanzant@investorideas.com

More Info:

This news is published on the Investorideas.com Newswire and its syndicated partner network

News now!

Get Investorideas.com investor news and stock alerts
Free Sign Up: http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news is paid for and /or published as information only for our readers.

Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. If you have any questions regarding information in this press release please contact the company listed in the press release.

Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp

Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

TOP